Rift Valley Fever Innovation Lab: Vaccination of livestock, subcutaneous with MP-12 and MP-12-NSm-del2

Abstract

Subcutaneous needle vaccination against Rift Valley fever virus (RVFV): Antibody response for goats,sheep and calves vaccinated with MP12 and MP12Nsm del vaccines analysed by PRNT 80% and commercial cELISAkit. cELISA results are expressed in inhibition percent (S/N%) and PRNT results in reciprocal of PRNT 80% neutralization titers. The overall purpose of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture is to increase the food supply by developing and applying a vaccine for the prevention of Rift Valley fever disease among livestock in Africa. Rift Valley Fever (RVF) is a mosquito-borne viral disease that continues to have a devastating impact on human and animal health in Africa. Since the discovery of RVF as the cause of an outbreak among sheep and humans during the early 1930s in the Rift Valley in Kenya, the disease has emerged as one of the most important zoonoses in Africa. The disease has and continues to affect the health of thousands to millions of humans and animals, and the livestock industry has lost millions of dollars, and therefore, affecting hundreds of millions of those whose livelihood depends on livestock, exaggerating poverty on already deprived communities.Full dataset available in the file: Livestock_vaccinated_with_MP-12_MP-12_NSm-del_SubQ_Salekwa.xlsx